Latest Guidance News

Carbonxt has added four US waste-to-energy facilities to its Reworld supply agreement, lifting annual Powdered Activated Carbon volumes by about 25% from January 2027. The expanded contract pushes the company’s FY27 revenue expectation to at least 40% above FY26, while Kentucky remains outside the forecast.

XRF Scientific has delivered its strongest September quarter in years, with revenue rising 38% to $21.1 million and profit before tax climbing 30% to $4.4 million. Orbis growth, resilient consumables demand and the developing CGA business are giving the company several avenues for further expansion, although precious metals revenue included a low-margin one-off sale.

Prescient Therapeutics has reached the first planned review threshold in its PTX-100 Phase 2a lymphoma study, while a completed A$6.0 million raise extends funding beyond the December milestone. The review will assess safety and efficacy, but is not a study completion or a new clinical result.

Elixinol Wellness has lifted combined hemp sales 12% to $6.41 million in the first nine months of 2026, while unaudited gross profit rose 41%. Two major grocery programs are now fully supplied through 2027, with Hemp Gold Protein due back at Costco in Australia and New Zealand.

Baby Bunting has reaffirmed its FY27 earnings and sales targets despite underlying comparable store sales growth moderating to 2.2% in the first 14 weeks. The retailer says its Store of the Future refurbishments are now delivering a 20% average sales uplift across 17 stores.

PainChek has expanded its Sabra relationship from two initial facilities to 23 US communities across five operators, covering 808 contracted memory care licences. The immediate test is whether those contracts become implemented recurring revenue by the end of 2026.

WiseTech Global’s FY26 annual report charts a year of extraordinary expansion, with revenue up 79% after the e2open acquisition and underlying EBITDA up 56%. But the stronger earnings base comes with heavier debt, a major workforce reset and unresolved regulatory risks.

Nyrada has received supportive written feedback from the US FDA on its proposed pathway for taking Xolatryp into a US Phase IIa heart-attack trial. The regulator identified no major issues, but additional information and stability data are still required before the planned IND submission in the first half of 2027.

Venari Minerals has exercised its option to acquire a Nevada property and private water entitlement near its Red Mountain Lithium Project for total consideration of US$400,000. The deal addresses a stated development constraint, although completion and the project’s broader economics remain ahead.

PGG Wrightson expects FY27 Operating EBITDA of approximately NZ$70 million, up from NZ$64.3 million in FY26, after an encouraging first quarter. The forecast rests on supportive commodity prices and farmer confidence, but remains exposed to input costs, weather and a planned reassessment after the second quarter.

Peninsula Energy’s low-pH uranium restart delivered stronger grades but failed to move enough solution through its Lance wellfields, forcing a guidance withdrawal and a US$50.1 million impairment. The company has fresh funding, but its auditor has warned of material uncertainty over its ability to continue as a going concern.

WhiteHawk has completed its Quixxi acquisition after shareholders approved every resolution with more than 95% of non-associated votes. The deal adds AI governance, mobile application security and an international customer base, but execution now matters more than the strategic pitch.